Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 04:44
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Openreach expands Optical Spectrum Access solution with 100G service powered by Adtran
Crime victims’ data revealed by two police forces in FoI responses
Lina Khan's rise was heralded as an antitrust revolution. Now she has to pull it off
Paralysed man regains feeling and movement with AI brain implant
FTC is investigating ChatGPT-maker OpenAI
SproutLoud Introduces Support for Brands with Complex Multi-Tier Distribution Channels
UFO expert claims that the south pole is a 'air traffic control' for aliens
Intel Innovation 2023: Empowering Developers to Bring AI Everywhere